Literature DB >> 25141860

Diffuse ventricular fibrosis measured by T₁ mapping on cardiac MRI predicts success of catheter ablation for atrial fibrillation.

Alex J A McLellan1, Liang-han Ling1, Sonia Azzopardi1, Andris H Ellims1, Leah M Iles1, Michael A Sellenger1, Joseph B Morton1, Jonathan M Kalman1, Andrew J Taylor1, Peter M Kistler2.   

Abstract

BACKGROUND: There is a complex interplay between the atria and ventricles in atrial fibrillation (AF). Cardiac magnetic resonance (CMR) imaging provides detailed tissue characterization, identifying focal ventricular fibrosis with late gadolinium enhancement (ventricular late gadolinium enhancement) and diffuse fibrosis with postcontrast-enhanced T1 mapping. The aim of the present study was to investigate the relationship between postcontrast ventricular T1 relaxation time on CMR and freedom from AF after pulmonary vein isolation. METHODS AND
RESULTS: One hundred three patients undergoing catheter ablation for symptomatic AF (66% paroxysmal AF; age, 58±10 years; left atrial area, 27±7 cm(2)) underwent preprocedure CMR to determine postcontrast ventricular T1 time. Follow-up included clinical review and 7-day Holter monitors at 6 monthly intervals. All patients underwent successful pulmonary vein isolation. At a mean follow-up of 15±7 months, the single procedure success was 74%. Postcontrast ventricular T1 time was significantly shorter in patients with recurrent AF (366±73 ms) versus patients without AF recurrence (428±90 ms; P=0.002). Univariate predictors of AF recurrence included postcontrast ventricular T1 time, AF type (paroxysmal versus persistent), AF duration, and body mass index. After multivariate analysis, ventricular T1 time (P=0.03) and AF duration (P=0.03) were the only independent predictors. Freedom from AF was present in 84% of patients with a postcontrast ventricular T1 time >380 ms versus 56% in patients with a postcontrast ventricular T1 time <380 ms (P=0.002).
CONCLUSIONS: A shorter postcontrast ventricular T1 relaxation time on CMR is associated with reduced freedom from AF after catheter ablation. Diffuse ventricular fibrosis as demonstrated by CMR may, in part, explain recurrent AF after AF ablation.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; fibrosis; magnetic resonance imaging

Mesh:

Substances:

Year:  2014        PMID: 25141860     DOI: 10.1161/CIRCEP.114.001479

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  10 in total

Review 1.  Applications of Advanced Imaging in Cardiac Electrophysiology.

Authors:  Mrinal Yadava; Michael D Shapiro
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

2.  Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial).

Authors:  Pavel Osmancik; Štěpán Havránek; Veronika Bulková; Jan Chovančík; Tomáš Roubíček; Dalibor Heřman; Zuzana Čarná; Vladimír Tuka; Martin Matoulek; Martin Fiala; Otakar Jiravský; Sylvie Stregl-Hruskova; Adam Latiňák; Jiřina Kotryová; Jiří Jarkovský
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

3.  Left ventricular native T1 time and the risk of atrial fibrillation recurrence after pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

Authors:  Shingo Kato; Murilo Foppa; Sébastien Roujol; Tamer Basha; Sophie Berg; Kraig V Kissinger; Beth Goddu; Warren J Manning; Reza Nezafat
Journal:  Int J Cardiol       Date:  2015-11-11       Impact factor: 4.164

4.  Left ventricular extracellular volume expansion does not predict recurrence of atrial fibrillation following catheter ablation.

Authors:  Suvai Gunasekaran; Daniel C Lee; Bradley P Knight; Jeremy D Collins; Lexiaozi Fan; Amar Trivedi; Ann B Ragin; James C Carr; Rod S Passman; Daniel Kim
Journal:  Pacing Clin Electrophysiol       Date:  2020-01-09       Impact factor: 1.976

5.  Left ventricular fibrosis by extracellular volume fraction and the risk of atrial fibrillation recurrence after catheter ablation.

Authors:  Songnan Li; Lei Zhao; Xiaohai Ma; Rong Bai; Jie Tian; Joseph B Selvanayagam
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

6.  The impact of tissue-tracking strain on the left atrial dysfunction in the patients with left ventricular dysfunction.

Authors:  Hideki Koike; Satoru Kishi; Naoki Hosoda; Shuhei Takemoto; Daijiro Tomii; Kai Ninomiya; Tetsu Tanaka; Masahiko Asami; Kazuyuki Yahagi; Kota Komiyama; Jun Tanaka; Hitomi Yuzawa; Rine Nakanishi; Tadashi Fujino; Jiro Aoki; Bharath A Venkatesh; João A C Lima; Kengo Tanabe; Takanori Ikeda
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-05

7.  Atrial fibrosis underlying atrial fibrillation (Review).

Authors:  Chang Yi Li; Jing Rui Zhang; Wan Ning Hu; Song Nan Li
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

Review 8.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

9.  Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation.

Authors:  Jay A Montgomery; Wissam Abdallah; Zachary T Yoneda; Evan Brittain; Sam G Aznaurov; Babar Parvez; Keith Adkins; S Patrick Whalen; J C Estrada; Sharon Shen; George H Crossley; Arvindh Kanagasundram; Pablo Saavedra; Christopher R Ellis; Mark Lawson; Dawood Darbar; M Benjamin Shoemaker
Journal:  J Arrhythm       Date:  2015-10-29

10.  Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy.

Authors:  Julian A Luetkens; Anne C Wolpers; Thomas Beiert; Daniel Kuetting; Darius Dabir; Rami Homsi; Hendrik Meendermann; Natalie Abou Dayé; Vincent Knappe; Morten Karsdal; Signe H Nielsen; Federica Genovese; Florian Stöckigt; Markus Linhart; Daniel Thomas; Georg Nickenig; Hans H Schild; Jan W Schrickel; René P Andrié
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.